Clinical Trial Update: Irinotecan and Carboplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating irinotecan plus carboplatin as first-line therapy for extensive-stage small cell lung cancer; results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-03-23